Investigation and Analysis of 932 Children with Adverse Drug Reactions Induced by Xiyanping Injection

Jia Xuelin; Wu Shifu; Huo Yanfei; Wang Ruiqin; Yan Meixing

doi:10.13407/j.cnki.jpp.1672-108X.2020.09.015

您当前的位置：

首页 >

文章列表页 >

Investigation and Analysis of 932 Children with Adverse Drug Reactions Induced by Xiyanping Injection

更新时间：2022-11-03

- Investigation and Analysis of 932 Children with Adverse Drug Reactions Induced by Xiyanping Injection
- Vol. 26, Issue 9, Pages: 49-53(2020)
- 作者机构：
  
  1. 大连医科大学,辽宁,大连,116044
  2. 山东省药品不良反应监测中心,山东,济南,250014
  3. 青岛市妇女儿童医院,山东,青岛,266034
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2020.09.015
  CLC：
- Published：2020，
  
  Published Online：10 September 2020，
扫描看全文
Jia Xuelin, Wu Shifu, Huo Yanfei, et al. Investigation and Analysis of 932 Children with Adverse Drug Reactions Induced by Xiyanping Injection. [J]. 26(9):49-53(2020)
DOI：

Jia Xuelin, Wu Shifu, Huo Yanfei, et al. Investigation and Analysis of 932 Children with Adverse Drug Reactions Induced by Xiyanping Injection. [J]. 26(9):49-53(2020) DOI： 10.13407/j.cnki.jpp.1672-108X.2020.09.015.

摘要

目的：调研分析932例喜炎平注射液在儿童用药引起的药品不良反应（ADR）的规律及其特点，为促进儿童临床合理用药提供参考。方法：采用回顾性分析方法，对山东省药品不良反应监测中心数据库中2015-2017年932例喜炎平注射液引起的儿童不良反应报告进行统计分析。结果：932例ADR报告中男568例（60.94%），女364例（39.06%），ADR发生的不同性别年龄分布比较差异无统计学意义（P>0.05）；婴幼儿ADR发生率最高，年龄0~1岁364例（39.06%），>1~3岁250例（26.82%）；ADR发生时间在30 min之内461例（49.46%）；给药途径采用静脉滴注896例（96.14%）；932例ADR共累及多个系统/器官共计1 320例次，最常见的临床表现是皮肤及其附件损害 (937例次，70.98%)；严重ADR 77例（8.26%），联合用药224例（24.03%）。结论：临床应加强喜炎平注射液的临床合理用药，掌握其适应证，尽可能的减少不良反应的发生。

Abstract

Objective: To investigate and analyze the characteristics and regularities of 932 children with adverse drug reactions (ADR) induced by Xiyanping injection

and provide references for promoting clinical rational drug use in children. Methods: Retrospective method was adopted

statistical analysis was conducted on 932 cases of ADR induced by Xiyanping injection from the database of Shandong Provincial Center for ADR monitoring from 2015 to 2017. Results: Among the 932 ADR reports

568 cases were male (60.94%)

364 cases were female (39.06%)

yet the difference was not statistically significant (P>0.05). The incidence of ADR in infants was the highest

with 364 cases (39.06%) aged from 0 to 1 year old

and 250 cases (26.82%) aged >1 to 3 years old. ADR occurred in 461 cases (49.46%) within 30 minutes. Intravenous drip was the main administration route

totally 896 cases (96.14%). Nine hundred and thirty-two cases of ADR involved multiple systems/organs

totally 1

320 cases

and the most common clinical manifestation was skin and its accessory lesions (937 cases

70.98%). There were 77 cases (8.26%) of severe ADR and 224 cases (24.03%) of drug combination. Conclusion: It is necessary to strengthen the rational clinical use of Xiyanping injection

grasp the clinical indications

and reduce the incidence of adverse drug reactions as much as possible.

关键词

喜炎平注射液儿童用药不良反应安全性

Keywords

Xiyanping injectionadverse drug reactions in childrensafety

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review on Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metabolic Disordersin Children

Efficacy of 2% Crisaborole Ointment in the Treatment of Mild to Moderate Atopic Dermatitis in Children

Safety Analysis of Thalidomide in Systemic Juvenile Idiopathic Arthritis

Efficacy and Safety of Tanreqing Injection in the Treatment of Children with Viral Pneumonia: a Meta-Analysis

Effect and Safety of Remazolam in Reducing Incidence of Agitation After Sevoflurane Anesthesia inChildren

Related Author

Li Huiying

Li Yunwei

Liu Yan

Shen Jianling

Lyu Mengwei

Tu Caixia

Yang Yanming

Ren Danyang

Related Institution

Kunming MedicalUniversity, Kunming

Kunming Children’s Hospital / Children’s Hospital of Kunming Medical University, Kunming

Wuxi Children’s Hospital

Shanghai Children’s Hospital, Children’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

The Central Hospital of Enshi Tujia andMiao Autonomous Prefecture, Hubei Enshi

⁰